Thinly traded nano cap Therapix Biosciences (TRPX +20.6%) is up on triple normal volume, albeit on turnover of only 331K shares, in response to positive preclinical data
on candidate THX-210, a pharmaceutical preparation containing
cannabidiol (CBD) and a naturally occurring anti-inflammatory molecule
called palmitoylethanolamide (PEA), that it intends to develop to treat epilepsy and inflammatory conditions.
Results from in vitro tests in hepatocyte models
of fat accumulation showed that the effect of CBD was enhanced by the
addition of PEA while PEA showed no effect alone, adding that THX-210
showed superior efficacy compared to CBD alone, the first time PEA has
demonstrated a synergistic effect on CBD in such a model.
Development is ongoing.
https://seekingalpha.com/news/3505787-therapix-bio-21-percent-encouraging-thxminus-210-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.